Skip to main content
. 2020 May 2;11(3):668–678. doi: 10.14336/AD.2020.0502

Table 1.

Characteristics of the included studies and meta-analysis of the clinical symptoms and comorbid chronic diseases in patients with COVID-19.

Study[ref]a NOS Dates (mm. yy) n
Age (years) Age ≥50 years (%) Symptoms (%)
Comorbidities(%)
All M F fever cough fatigue or myalgia shortness of breath or dyspnea diarrhea diabetes hypertension CAD/CVD chronic pulmonary disease
Guan et al.,2020 [3] 8 12.19-01.20 1099 640 459 47.0 44.0 88.7 67.8 38.1 18.7 3.8 7.4 15.0 2.5 1.1
Chen et al.,2020 [4] 7 01.20-01.20 99 67 32 55.5 67.7 82.8 81.8 11.0 31.3 2.0 13.0 b 40.0 1
Huang et al.,2020 [18] 6 12.19-01.20 41 30 11 49.0 48.8 98.0 76.0 44.0 55.0 3.0 20.0 15.0 15.0 2.0
Liu et al.,2020 [8] 7 12.19-01.20 137 61 76 55.0 b 81.8 48.2 32.1 19.0 8.0 10.2 9.5 7.3 1.5
Shi et al.,2020 [22] 6 12.19-01.20 81 42 39 49.5 49.4 73.0 59.0 b 42.0 4.0 12.0 15.0 10.0 11
Song et al.,2020 [20] 6 01.20-01.20 51 25 26 49.0 47.1 96.0 47.0 31.0 14.0 10.0 6.0 10.0 2.0 2.0
Yang et al.,2020 [6] 7 12.19-01.20 52 35 17 59.7 55.0 98.0 77.0 11.5 63.5 b 17.0 b 10.0 8
Xu et al.,2020 [19] 7 01.20-01.20 62 35 27 41.0 b 77.0 81.0 52.0 b 8.0 2.0 8.0 b 2.0
Zhang et al.,2020 [15] 8 01.20-02.20 140 71 69 57.0 70.0 78.6 64.3 64.3 31.4 12.9 12.1 30.0 5.0 2.8
Wu et al.,2020 [16] 7 01.20-02.20 80 39 41 46.0 35.0 78.8 63.8 22.5 37.5 1.3 6.3 b 31.3 1.25
Hu et al.,2020 [14] 6 01.20-02.20 24 8 16 32.5 37.5 20.8 8.3 8.3 b b 8.3 8.3 4.2 0.0
Huang et al.,2020 [17] 7 12.19-01.20 34 14 20 56.2 b 94.1 50.0 64.7 14.7 14.7 11.8 23.5 17.6 8.8
Yang et al.,2020 [13] 8 01.20-02.20 149 81 68 45.1 b 76.5 58.4 3.4 1.3 7.4 6.0 b 18.8 0.7
Wang et al.,2020 [5] 7 01.20-01.20 138 75 63 56.0 b 98.6 59.4 69.6 31.2 10.1 10.1 31.2 14.5 2.9
Xu et al.,2020 [21] 7 01.20-02.20 90 39 51 50.0 b 78.0 63.0 28.0 b 6.0 6.0 19.0 3.0 1.0
Li et al.,2020 [12] 7 01.20-02.20 83 44 39 45.5 b 86.7 78.3 18.1 10.8 8.4 7.8 6.0 1.2 6.0
Shi et al.,2020 [23] 8 01.20-02.10 416 205 211 64 b 80.3 34.6 13.2 28.1 3.8 14.4 30.5 10.6 2.9
Bhatraju et al.,2020[24] 6 02.20-03.20 24 15 9 64 b 50.0 88.0 b 88.0 b 58.0 b b 16.7
Feng et al.,2020 [25] 7 01.20-02.20 476 271 205 53 b 81.9 56.5 11.6 22.9 10.3 10.3 23.7 8.0 4.6
Du et al.,2020 [26] 8 12.19-02.20 179 97 82 57.6 72.6 98.9 81.6 39.7 49.7 21.8 18.4 32.4 16.2 4.5
Liu et al.,2020 [27] 6 12.19-01.20 78 39 39 38 b 73.1 43.6 b b b 6.4 10.3 b 2.6
Grasselli et al.,2020 [28] 8 02.20-03.20 1591 1304 287 63 87.2 b b b b b 11.3 32.0 14.0 2.6
Richardson et al.,2020[29] 8 03.20-04.20 5700 3437 2263 63 78.5 30.4 b b 17.3 b 31.8 53.0 16.9 8.4
Simonnet et al.,2020[30] 7 02.20-04.20 124 90 34 60 1.00 b b b b b 22.6 48.4 b b
Total/Overall 12.19-04.20 10948 6764 4184 52.4c
(32.5-64.0)d
Prevalencee 59.0 79.0 61.0 32.0 31.0 7.0 10.0 20.0 8.0 3.0
95% CI 49.0-68.0 65.0-92.0 54.0-69.0 21.0-43.0 25.0-
37.0
5.0-9.0 8.0-12.0 15.0-26.0 3.0-12.0 1.0-3.0
I2 (%) 98.5 99.7 95.1 98.5 97.4 81.1 73.0 94.2 98.0 94.5

mm, month; yy, year; M, male; F, female; SE, standard error; CI, confidence interval, NOS, Newcastle-Ottawa Scale;

a

[3]- [8], [12]-[23], [25]-[27] Studies were from China; [24], [29] studies were from America; [28] study was from Italy; [30] study was from France.

b

Any empty cells represents the absence of data in the original text.

c

the median age [IQR].

d

Age range.

e

Meta-analysis for the prevalence was calculated from binary random-effects model analysis.

f

p < 0.001.